ESCAPE Bio is a clinical stage, privately held biopharmaceutical company developing novel, precisely targeted therapeutics for genetically defined neurodegenerative diseases. ESB1609 is in a Phase 1 multiple ascending dose study in healthy volunteers. ESCAPE has advanced a mutant-selective LRRK2 G2019S kinase inhibitor for Parkinson's Disease (PD) patients to IND-enabling studies. A pharmacologic structure corrector of Alzheimer's patients carrying the ApoE4 risk allele is in Discovery.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/14/20 | $73,000,000 | Crossover Financing |
Avidity Partners CAM Capital Johnson & Johnson Innovation New Leaf Venture Partners Novartis Venture Funds Novo Holdings OrbiMed Advisors Osage University Partners Rock Springs Capital Sphera Funds Management Surveyor Capital Wellington Management Company  | undisclosed |
